PDCD1 and atherosclerosis: This indicates that CTLA-4 inhibition, like PD-1 inhibition, induces an activated phenotype of T cells, and the inhibition of different immune checkpoint pathways has differential effects on the activation of immune cell components in atherosclerosis (Figure 2).